The Detection of Cardiotoxicity during Cancer Therapy: Biomarkers and/or Imaging
International CardiOncology Society (ICOS) Annual Meeting: Day 1

7:20 am to 8:20 am
Registration & Continental Breakfast

8:20 am to 8:30 am
Introduction: Carlo Cipolla, MD and Daniel Lenihan, MD

8:30 am to 8:40 am
Welcome: Professor Umberto Veronesi

8:40 am to 10:20 am (Session 1)
Overview of Cardiotoxicity and the Potential Impact
Moderators: Giuseppe Curigliano, MD, PhD / Joseph Carver, MD
• Integrating the critical role of anthracyclines in cancer therapy and the risk of cardiotoxicity: Giorgio Minotti, MD (20 minutes)
• Understanding the biology of cardiac injury is critical to new drug development: Douglas Sawyer, MD, PhD (20 minutes)
• Late cardiotoxicity: legend or reality?: Daniela Cardinale, MD, PhD (20 minutes)
• Panel Discussion: All speakers (40 minutes)

10:20 am to 10:40 am
Break

10:40 am to 12:20 pm (Session 2)
Anti-angiogenic Therapy in Oncology – is there a Cardiac Concern?
Moderators: Daniel Lenihan, MD / Carlo Tocchetti, MD, PhD
• How useful are anti-angiogenic therapies in cancer treatment?: Apostolia Tsimberidou, MD, PhD (20 minutes)
• Is there evidence for a biomarker strategy for cardiac toxicity detection with anti-angiogenic agents?: Bonnie Ky, MD (20 minutes)
• Angiogenesis/Anti-angiogenesis: Where can cardiology and oncology find common beneficial targets?: Invited (20 minutes)
• Panel Discussion: All Speakers (40 minutes)

12:20 pm to 1:20 pm
Lunch

1:20 pm to 2:50 pm (Session 3)
Newer Biomarkers for the Detection of Cardiotoxicity
Moderators: Douglas Sawyer, MD, PhD / Jean-Bernard Durand, MD
• High sensitivity Troponins and Natriuretic Peptides in the early detection of cardiotoxicity: Maria Teresa Sandri, MD (20 minutes)
• Mitochondrial mechanisms and markers of cardiotoxicity: Marco Giorgio, MD, PhD (20 minutes)
• MAO Inhibitors for protection and treatment of cardiotoxicity: Fabio Di Lisa, MD (20 minutes)
• Panel Discussion: All speakers (30 minutes)

2:50 pm to 3:10 pm
Break

3:10 pm to 4:40 pm (Session 4)
Management, Guidelines, and Trial Conduct for Cardiac Issues in Oncology
Moderators: Ron Krone, MD / Vittorio Mattioli, MD
• High dose chemotherapy & stem cell transplantation – How do Oncology & Cardiology Interact with these patients?: Fabio Ciceri, MD (20 Minutes)
• Guidelines for the prevention and management of cardiac co-morbidity in Hematology Oncology: Giovanni Barosi, MD (20 minutes)
• How can cardiology help in the development and conduct of oncology clinical trials?: Thomas Suter, MD (20 minutes)
• Panel Discussion: All speakers (30 minutes)

4:40 pm to 4:50 pm
Break

4:50 pm to 5:50 pm (Session 5)
State of the Art of CardiOncology
Moderators: Carol Chen, MD / Giovanni La Canna, MD
• Echocardiography can be a mainstay for ensuring cardiac safety during cancer therapy: Carlo Tocchetti, MD, PhD (20 minutes)
• Research opportunities that arise in the overlap between Cardiology & Oncology: Giuseppe Curigliano, MD, PhD (20 minutes)
• Panel Discussion: All speakers (20 minutes)

5:50 pm to 6:20 pm
Poster Session
Moderators: Alessandro Colombo, MD and Carlo Cipolla, MD
International CardiOncology Society (ICOS) Annual Meeting: Day 2

7:20 am to 8:20 am
Registration & Continental Breakfast

8:20 am to 8:30 am
Introduction: Daniel Lenihan, MD and Professor Cesare Fiorentini

8:30 am to 10:10 am (Session 6)
Cardiac Imaging in Oncology Trials
Moderators: Richard Steingart, MD / Maurizio Civelli, MD
- How should the detection of cardiotoxicity be incorporated into phase II and III clinical trials of breast cancer therapy? Chau Dang, MD Oncology and Jennifer Liu, MD Cardiology (30 minutes)
- Overview of newer techniques in Echo, including 3-D and contrast vector imaging to detect cardiotoxicity: Jagat Narula, MD, PhD (20 minutes)
- Is Echo or MRI the test of choice to detect toxicity in all patients or a select few?: Invited (20 minutes)
- Panel Discussion: All speakers (30 minutes)

10:10 am to 10:30 am
Break

10:30 am to 12:30 pm (Session 7)
Enhancing Cooperation with Cardiology and Oncology
Moderators: Antonio Pezzano, MD / Boaz Mendezlevski, MD
- How do we integrate biomarkers and imaging in a clinically practical manner to detect cardiotoxicity?: Daniel Lenihan, MD (20 minutes)
- What is the optimal strategy to ensure cardiac safety during oncology drug development?: John Finkle, MD (20 minutes)
- What should cardiology and oncology’s practice goals be to achieve synergy?: Michael Fisch, MD (20 minutes)
- What can professional societies do to better integrate care?: JoAnn Lindenfeld, MD (20 minutes)
- Panel Discussion: All Speakers (40 minutes)

12:30 pm to 12:40 pm
Closing Remarks – Plan for CardiOncology 2013
Carlo Cipolla, MD / Daniel Lenihan, MD